Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Persistence of Immunity to Hepatitis B with Engerix-B
NCT02901951Phase 4Completed
- Sponsor
- GSK
- Start
- Oct 2016
- Primary completion
- May 2017
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of hepatitis b vaccine recombinant in hepatitis B (HBV), sponsored by GSK. Primary endpoint: Percentage of Subjects With an Anamnestic Response to the HBV Challenge Dose at 30 days. Started Oct 2016; status: completed.
02
Drugs
hepatitis b vaccine recombinant
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT02901951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02901951.